{"id":535829,"date":"2021-09-08T16:03:10","date_gmt":"2021-09-08T20:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/"},"modified":"2021-09-08T16:03:10","modified_gmt":"2021-09-08T20:03:10","slug":"cytokinetics-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/","title":{"rendered":"Cytokinetics to Participate in September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>H.C. Wainwright 23rd Annual Global Investment Conference <\/strong>on Monday, September 13, 2021 at 12:00 PM EDT in a virtual presentation available for on-demand viewing<\/li>\n<li style=\"text-align:justify\">\n          <strong>Morgan Stanley 19th Annual Global Healthcare Conference <\/strong>on Tuesday, September 14, 2021 at 11:45 AM EDT in a virtual fireside chat<\/li>\n<li style=\"text-align:justify\">\n          <strong>Cantor Virtual Global Healthcare Conference <\/strong>on Monday, September 27, 2021 at 3:20 PM EDT in a virtual presentation<\/li>\n<\/ul>\n<p align=\"justify\">Interested parties may access the on-demand and live webcasts of each presentation by visiting the Investors &amp; Media section of the Cytokinetics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VlqEYBv9-CrsZ2Y8nKqW423M10TIRCIlezm_j2gS2V4B7p6-psfjPO73d9rJP6ZOPbWXsqciinB69F3MFt78lsDdyJmdKRLqv2a4ujCqc7Q=\" rel=\"nofollow noopener\" target=\"_blank\">www.cytokinetics.com<\/a>. The replay of each presentation will be archived on the Presentations page within the Investors &amp; Media section of Cytokinetics&#8217; website for 90 days following the conclusion of the event.<\/p>\n<p>\n        <strong>About Cytokinetics<\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and\/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing a U.S. NDA submission of <em>omecamtiv mecarbil<\/em>, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of <em>omecamtiv mecarbil<\/em>. Cytokinetics is also developing <em>aficamten<\/em>, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The company has announced positive topline results from Cohorts 1 and 2 in REDWOOD-HCM, a Phase 2 clinical trial of <em>aficamten<\/em> in patients with obstructive HCM. Cytokinetics expects to start a Phase 3 clinical trial of <em>aficamten<\/em> in patients with obstructive HCM in Q4 2021. Cytokinetics is also developing <em>reldesemtiv<\/em>, a fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.<\/p>\n<p align=\"justify\">For additional information about\u00a0Cytokinetics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VlqEYBv9-CrsZ2Y8nKqW40RhPzAkp41Rk-OPz43_sLpRE9a-RenQpdkg487iWcOWJzt2iDm6v7GMf6pdauQMySYjMwk5QFNb5AC7_5CZ8ncreU5hGPXFYRQQ03u1PXKFMeebzEFhZHRP9zuM6cvllui2g-X5axdidTcUZfvbVgVC9ubu5JZ1r7qU7YceFUVhA8OGJTM9zP7y2SNNdtv5iO5V5rCDwb8HQEkffVjdeMCJoOTUoluwghqbzxEr3PD7dnL1eUTAecNgNIG2-sLPCqP6H2JyE5CmHwJsaZAmTbqSOFjXNEih1hsaXZDDkwHy3cP6F896uk6BKMkJhoP7PDJypE-aX_lnKO6O_nR9nATFmVAK_hGS-gQ77BKtA30N_9Oj8f_U1nUo008TIU_HSe0Z5_YStt0z-2wJ3WiDt4sC8aI0GG5suM9-Ar-kgLUOKEdbL4bNBf1vlIVwTfQGb2x97RNgBgdRMccAY6_f6d1wnk_b-RJBAG-LaRs5fpBIL-oFHy5eopkbOwhWQG4yVhTZt5XglfwIG2D4m4UxOpYZUHQVd2EVMssJFKUyqF-2EKmT732nf-KDb0k8deCiAi1oHIRnxHYIVZMEk7pjcpCQo2p4clDUpwdJLaMl0BLSG2dd1HJ7CKOsrufmgvJ1hxambRtu4owC0Vng0T7Ld28P48nZHv_to-8gTmZijylM8Da20L2pa0bo64ANeXPh-bWAt4tXUGP_Uu7e0jWSs3kFdrIsfliYhTVGbQnEMKW3c0Eqk_QQ854YmiUtlBBaVw==\" rel=\"nofollow noopener\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NhjGRdRJrk2AusjvD-gvsMmHTXDuVseY9eCfaNTwqoMikW-yCc4vvt0yaqv0vcvJm3-hZ6AiDwhUDsiAJpddwg==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UVxpo3vMjZPhwaOLDfP9LA5LsgzvuKERbkJaS3_PzWFoNHo7ynoPqnaq9htxZr7tNKC108DmopmCPMfvq4howbrrT72xKYqXc6XHs9ni_ew=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=adDSn0cIEWbs--gCHgA7kR_VWyGzJ-mMaU3_ldVKgccO3bSnC4sgRlwy3grRpXZhy7WG_aWu09_MBMyPJz7-ThTOAyVbnFUNS3y7QIsdnPk=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xkm3v71Xv0kGhlZhFjnRuwFtmvXBGuf6V7EeC87pIhXO2kylx6Cbm2hD2d0IehBzw5Qog4HxNTzcygKmKj9SqxS5w6Y61nSAKGuVI356I03pUUc2tiXk812hDjVJLih5\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act&#8217;s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics&#8217; and its partners&#8217; research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics&#8217; business outlined in Cytokinetics&#8217; filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics&#8217; actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">Contact:<br \/>Cytokinetics<br \/>Diane Weiser<br \/>Senior Vice President, Corporate Communications, Investor Relations<br \/>(415) 290-7757<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTkzZWNlYjktZGJkZi00ZTM5LWJkZTMtMjI0M2NmMDQ3ZDhhLTEwMTY2NzY=\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 12:00 PM EDT in a virtual presentation available for on-demand viewing Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 11:45 AM EDT in a virtual fireside chat Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 3:20 PM EDT in a virtual presentation Interested parties may access the on-demand and live webcasts of each presentation by visiting the Investors &amp; Media section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535829","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 12:00 PM EDT in a virtual presentation available for on-demand viewing Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 11:45 AM EDT in a virtual fireside chat Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 3:20 PM EDT in a virtual presentation Interested parties may access the on-demand and live webcasts of each presentation by visiting the Investors &amp; Media section of the &hellip; Continue reading &quot;Cytokinetics to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T20:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics to Participate in September Investor Conferences\",\"datePublished\":\"2021-09-08T20:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":592,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Cytokinetics to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\",\"datePublished\":\"2021-09-08T20:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics to Participate in September Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 12:00 PM EDT in a virtual presentation available for on-demand viewing Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 11:45 AM EDT in a virtual fireside chat Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 3:20 PM EDT in a virtual presentation Interested parties may access the on-demand and live webcasts of each presentation by visiting the Investors &amp; Media section of the &hellip; Continue reading \"Cytokinetics to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T20:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics to Participate in September Investor Conferences","datePublished":"2021-09-08T20:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/"},"wordCount":592,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/","name":"Cytokinetics to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=","datePublished":"2021-09-08T20:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc0MSM0MzkzMzg1IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535829"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535829\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}